Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(iv) prodrugs

Author affiliations

Abstract

The dysregulation of apoptosis and DNA damage repair are two leading mechanisms of cisplatin resistance. Two anticancer PtIV prodrugs with the formulas [Pt(NH3)2Cl2(L1)2] (1, L1 = 3-chloro-benzo[b]thiophene-2-carboxylic acid) and [Pt(NH3)2Cl2(L2)2] (2, L2 = 3-chloro-6-methylbenzo[b]thiophene-2-carboxylic acid) were designed to target myeloid cell leukemia-1 (Mcl-1), a protein responsible for inhibiting apoptosis and promoting DNA damage repair. Complexes 1 and 2 exhibited high cytotoxicity against various cancer cell lines, especially cisplatin-resistant non-small-cell lung and ovarian cancer cells. The resistance factors of both complexes for cisplatin-resistant cancer cells also decreased markedly as compared with that of cisplatin. Both 1 and 2 could enter cancer cells effectively and cause DNA damage while simultaneously downregulating Mcl-1 to prompt a conspicuous apoptotic response. Complex 2 also downregulated the DNA damage repair proteins RAD51 and BRCA2 as well as inhibited the formation of RAD51 foci, which is regarded as a critical step and functional biomarker in homologous recombination. The acute toxicity of 1 and 2 to mice is lower than that of cisplatin, and more importantly, they show much stronger inhibition towards the growth of non-small-cell lung cancer in nude mice than cisplatin. Complexes 1 and 2 are the first Mcl-1-targeted PtIV prodrugs, and the latter could synchronously inhibit apoptosis and DNA repair related proteins in cisplatin-resistant cancer cells. The strategy of tuning both apoptosis and DNA repair pathways opens a promising window to overcoming resistance to cisplatin in anticancer chemotherapy, and is also a breakthrough in the design of multitalented platinum-based anticancer drugs.

Graphical abstract: Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(iv) prodrugs

Back to tab navigation

Supplementary files

Article information


Submitted
13 Jan 2020
Accepted
20 Feb 2020
First published
09 Mar 2020

This article is Open Access
All publication charges for this article have been paid for by the Royal Society of Chemistry

Chem. Sci., 2020, Advance Article
Article type
Edge Article

Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(IV) prodrugs

S. Zhang, X. Zhong, H. Yuan, Y. Guo, D. Song, F. Qi, Z. Zhu, X. Wang and Z. Guo, Chem. Sci., 2020, Advance Article , DOI: 10.1039/D0SC00197J

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

Reproduced material should be attributed as follows:

  • For reproduction of material from NJC:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
  • For reproduction of material from PCCP:
    [Original citation] - Published by the PCCP Owner Societies.
  • For reproduction of material from PPS:
    [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
  • For reproduction of material from all other RSC journals:
    [Original citation] - Published by The Royal Society of Chemistry.

Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.


Social activity

Search articles by author

Spotlight

Advertisements